Fuse Oncology and AMP NY Partner to Test Integrated Radiation Oncology Workflow

Key facts

According to a press release issued by Fuse Oncology via PRNewswire, the technology firm has partnered with Associated Medical Professionals of NY (AMP) to deploy and refine an integrated workflow system designed specifically for radiation oncology within a community urology practice environment. The trial program, established as a proof of concept, seeks to connect the software systems and clinical pathways used by urologists and radiation oncologists into a synchronized operational platform.

In typical outpatient settings, urology practices that offer radiation therapy must navigate separate software applications for patient scheduling, CT simulation, treatment planning, linear accelerator control, dose verification, and specialized oncology billing. In many community medical groups, these radiation-specific systems operate independently from the primary electronic health record system used during initial consultations and surgical follow-ups.

Under the proof-of-concept project, Fuse Oncology and AMP are deploying software designed to bridge these technological gaps. The pilot evaluates how automated clinical data transfers, synchronized scheduling, real-time patient tracking, and consolidated documentation perform in a live clinical practice setting across AMP's facilities in New York State. Neither organization disclosed the financial terms of the agreement or the exact duration of the evaluation phase in the initial public statement.

Why it matters

The launch of this proof of concept reflects a ongoing shift in outpatient specialty medicine toward integrated, single-site cancer care. Prostate cancer represents one of the most frequently diagnosed malignancies in men worldwide, and clinical care pathways routinely combine surgical intervention, active surveillance, hormone therapy, and external beam radiation therapy. Historically, patients requiring radiation treatment were referred outside the urology practice to hospital-based departments or independent centers, which often led to fragmented medical records, communication delays, and duplicated administrative procedures.

For large specialty medical groups like AMP and management platforms like U.S. Urology Partners, establishing a streamlined radiation oncology workflow offers clear operational and organizational benefits. Bringing radiation therapy into community urology networks allows practices to retain patients within a single continuous care environment. However, operating advanced linear accelerators and radiation treatment planning software requires strict adherence to safety protocols, intricate treatment planning, and multi-step insurance precertification.

Operational bottlenecks in radiation departments can lead to delays in treatment delivery, increase administrative workloads for clinical staff, and result in billing errors. Software solutions that automate data exchange between general electronic health records and specialized radiation platforms can shorten the time between diagnosis and treatment start dates. By reducing manual data entry, integrated workflows also mitigate the risk of administrative transcription errors in treatment orders, dose delivery records, and insurance claims. If successful, the proof of concept could establish a standardized model for other private equity-backed specialty practices seeking to expand in-house radiation oncology services.

Integrated community urology has expanded significantly over the past two decades across the United States, driven by technological advances, evolving reimbursement structures, and substantial private equity investment. Historically, community urology practices focused primarily on diagnostic procedures, medical management, and outpatient surgical interventions. As radiation therapy technology advanced—particularly with the widespread adoption of intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and stereotactic body radiation therapy (SBRT)—large urology groups increasingly invested in linear accelerators and hired onsite radiation oncologists and medical physicists to provide comprehensive cancer care.

Associated Medical Professionals of NY (AMP) developed as a major multi-specialty urological practice serving patients across Central and Upstate New York, including the Syracuse and Utica areas. To expand its clinical footprint, recruit specialized providers, and fund capital expenditures for advanced medical equipment, AMP affiliated with U.S. Urology Partners. U.S. Urology Partners operates as a physician practice management company formed to build an integrated network of urology practices across multiple states, supported by capital and strategic guidance from General Atlantic, a global growth equity firm with extensive investments in healthcare services and technology.

At the technical level, radiation oncology is one of the most software-intensive specialties in modern healthcare. A standard course of radiation therapy involves continuous interactions between an electronic health record (EHR) system, a computed tomography (CT) simulator, a treatment planning system (TPS), and a record-and-verify (R&V) system attached to a linear accelerator. In many clinical environments, these systems are created by different commercial vendors, resulting in software silos that require manual data entry, physical documentation, or complex custom interfaces.

Fuse Oncology was established to address these software interoperability challenges in radiation therapy departments. The company's technology platform is designed to operate alongside existing health information systems, consolidating clinical and operational data to give clinical teams real-time visibility into patient care pathways, prior authorization status, scheduling tasks, and compliance documentation.

Reaction

Because the announcement was issued directly by Fuse Oncology, formal public reactions from external medical associations, regulatory agencies, or competing technology vendors have not been released. Neither the American Urological Association (AUA) nor the American Society for Radiation Oncology (ASTRO) has issued a statement regarding this specific commercial trial.

Healthcare industry analysts and practice executives in the private equity healthcare sector are expected to track the program's outcomes closely. Executive management at U.S. Urology Partners and General Atlantic will likely monitor the trial to assess whether the Fuse Oncology platform delivers a measurable return on investment through reduced administrative labor, faster care delivery, and enhanced billing accuracy. Additionally, radiation oncologists, medical physicists, and practice managers within community urology groups will evaluate whether the platform reduces daily workflow friction without adding administrative complexity to treatment verification protocols.

What we don't know yet

Several key operational and technical details regarding the proof-of-concept program were omitted from the initial announcement:

These missing metrics are critical for evaluating whether the software integration can be deployed effectively across other medical practices under the U.S. Urology Partners network or adopted by independent urology groups using different electronic health record platforms.

What to watch

Over the coming months, several key indicators will determine the progress and broader applicability of this initiative:

This article is based on reporting published by Fuse Oncology via PRNewswire on September 29, 2026.